2020
Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies
Menter A, Gelfand JM, Connor C, Armstrong AW, Cordoro KM, Davis DMR, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Prater EF, Rahimi RS, Rupani RN, Siegel M, Stoff B, Strober BE, Tapper EB, Wong EB, Wu JJ, Hariharan V, Elmets CA. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. Journal Of The American Academy Of Dermatology 2020, 82: 1445-1486. PMID: 32119894, DOI: 10.1016/j.jaad.2020.02.044.Peer-Reviewed Original ResearchMeSH KeywordsAcitretinCyclosporineDrug MonitoringHumansMethotrexatePiperidinesPsoriasisPyrimidinesThalidomideConceptsDermatology–National Psoriasis Foundation guidelinesManagement of psoriasisTreatment of psoriasisChronic inflammatory diseaseFumaric acid estersMultiple organ systemsJoint American AcademyNonbiologic medicationsNonbiologic therapiesInflammatory diseasesFoundation guidelinesNew therapiesAmerican AcademyOrgan systemsMedicationsPsoriasisTherapyTreatmentDiseaseGuidelinesTofacitinibAcitretinPatientsApremilastPrescribers
2016
Treatment of Moderate to Severe Pediatric Psoriasis: A Retrospective Case Series
Klufas D, Wald J, Strober B. Treatment of Moderate to Severe Pediatric Psoriasis: A Retrospective Case Series. Pediatric Dermatology 2016, 33: 142-149. PMID: 26871417, DOI: 10.1111/pde.12782.Peer-Reviewed Original ResearchConceptsSevere pediatric psoriasisRetrospective case seriesPediatric psoriasisCase seriesSevere psoriasisSystemic therapySide effectsDisease responseSimilar side effect profilePhysician Global Assessment scaleComprehensive safety profileSmall sample sizeSingle referral centerSubjective side effectsSide effect profileSafety of treatmentMultiple treatment optionsAdverse event occurrenceComparison of efficacyGlobal Assessment ScalePaucity of dataAdult psoriasisImmunomodulating therapiesAdverse eventsReferral center
2015
Current and Future Oral Systemic Therapies for Psoriasis
Kelly J, Foley P, Strober B. Current and Future Oral Systemic Therapies for Psoriasis. Dermatologic Clinics 2015, 33: 91-109. PMID: 25412786, DOI: 10.1016/j.det.2014.09.008.Peer-Reviewed Original ResearchMeSH KeywordsAcitretinAnti-Inflammatory Agents, Non-SteroidalAntimetabolitesCyclosporineFumaratesHumansHydroxyureaImmunosuppressive AgentsIsoxazolesKeratolytic AgentsLeflunomideMethotrexateMycophenolic AcidPiperidinesProtein Kinase InhibitorsPsoriasisPyrimidinesPyrrolesSulfasalazineThalidomideThioguanine
2006
Conventional systemic agents for psoriasis. A systematic review.
Strober B, Siu K, Menon K. Conventional systemic agents for psoriasis. A systematic review. The Journal Of Rheumatology 2006, 33: 1442-6. PMID: 16724368.Peer-Reviewed Original Research
2004
Etanercept for the treatment of psoriasis: combination therapy with other modalities.
Strober B, Clarke S. Etanercept for the treatment of psoriasis: combination therapy with other modalities. Journal Of Drugs In Dermatology 2004, 3: 270-2. PMID: 15176161.Peer-Reviewed Original ResearchMeSH KeywordsAcitretinAdultAnti-Inflammatory Agents, Non-SteroidalAntirheumatic AgentsArthritis, PsoriaticCyclosporineDose-Response Relationship, DrugDrug Therapy, CombinationEtanerceptFemaleHumansImmunoglobulin GKeratolytic AgentsMaleMiddle AgedPsoriasisReceptors, Tumor Necrosis FactorRecombinant Fusion ProteinsConceptsTumor necrosis factorTumor necrosis factor receptorWeekly doseRheumatoid arthritisPatients of psoriasisPlacebo-controlled studySevere plaque psoriasisSelf-administered medicationsJuvenile rheumatoid arthritisTreatment of psoriasisHuman fusion proteinNecrosis factor receptorPlaque psoriasisContinuous therapyPsoriasis AreaPsoriatic arthritisSystemic therapyPsoriasis patientsTreatment regimenClinical efficacyCombination therapyMedical historyClinical trialsNecrosis factorEtanercept